Please note: The information displayed on this page might be outdated.
Plexium: Plexium is an emerging biotechnology company focused on the rational design of monovalent protein degrading therapeutics to treat cancer and other serious diseases. Plexium’s targeted protein degradation platform, DELPhe®, enables the discovery of novel small molecules with cell-based activity that redirect E3 ligases to pathogenic proteins of interest or induce degradation of pathogenic proteins by directly binding to them. Plexium is advancing a pipeline of wholly-owned targeted oncology and immune-oncology drug candidates. In addition, Plexium has an active drug discovery collaboration with Amgen to discover novel E3 ligase modulating small molecule therapeutics.
Company Participants at Fall Private Company Showcase 2021
- Kevin Eastwood, Vice President, Business Development